Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer
Presented: American Society of Clinical Oncology Annual Meeting, 29 May 2026, Chicago, IL
Presenter: Lucy Gilbert, MD, MSc, FRCOG
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.